Ghent University Academic Bibliography

Journal Article
A1
open access

Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia

Stien De Coninck, Juliette Roels (UGent) , Béatrice Lintermans (UGent) , Sara T'Sas (UGent) , Tom Taghon, David Curtis, Tim Pieters (UGent) , Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)

(2024) BLOOD ADVANCES. 8(11). p.2646-2649

Add to list

Journal Article
A1
open access

A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation

Romy M. W. de Laat-Kremers, Denis Wahl, Stephane Zuily, Marisa Ninivaggi, Veronique Regnault, Jacek Musial, Philip G. de Groot, Katrien Devreese (UGent) and Bas de Laat

(2024) BLOOD ADVANCES. 8(4). p.936-946

Add to list

Journal Article
A1
open access

A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML

Zhiyao Ren (UGent) , Jolien Vanhooren (UGent) , Charlotte Derpoorter (UGent) , Barbara De Moerloose (UGent) and Tim Lammens (UGent)

(2024) BLOOD ADVANCES. 8(12). p.3299-3310

Add to list

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey

Jaap A. van Doesum, Jon Salmanton-García, Francesco Marchesi, Roberta Di Blasi, Iker Falces-Romero, Alba Cabirta, Francesca Farina, Caroline Besson, Barbora Weinbergerová, Jens Van Praet (UGent) , et al.

(2023) BLOOD ADVANCES. 7(11). p.2645-2655

Add to list

Journal Article
A1
open access

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL : the HOVON-100 trial

Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjen A. van de Loosdrecht, Lotte E. van der Wagen, Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, et al.

(2022) BLOOD ADVANCES. 6(4). p.1115-1125

Add to list

Journal Article
A1
open access

Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Claire Dearden, Sebastian Grosicki, et al.

(2022) BLOOD ADVANCES. 6(11). p.3440-3450

Add to list

Journal Article
A1
open access

Myb drives B-cell neoplasms and myeloid malignancies in vivo

Tim Pieters (UGent) , André Pedro Pinto De Almeida (UGent) , Sara T'Sas (UGent) , Kelly Lemeire (UGent) , Tino Hochepied (UGent) , Geert Berx (UGent) , Alex Kentsis, Steven Goossens (UGent) and Pieter Van Vlierberghe (UGent)

(2022) BLOOD ADVANCES. 6(10). p.2987-2991

Add to list

Journal Article
A1
open access

Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry : a multicentric study

Sebastian Böttcher, Robby Engelmann, Georgiana Grigore, Paula Carolina Fernandez, Joana Caetano, Juan Flores-Montero, Vincent H.J. van der Velden, Michaela Novakova, Jan Philippé (UGent) , Matthias Ritgen, et al.

(2022) BLOOD ADVANCES. 6(3). p.976-992

Add to list

Journal Article
A1
open access

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death

Eva De Smedt, Julie Devin, Catharina Muylaert, Nicolas Robert, Guilhem Requirand, Philip Vlummens, Laure Vincent, Guillaume Cartron, Ken Maes, Jerome Moreaux, et al.

(2021) BLOOD ADVANCES. 5(9). p.2325-2338

Add to list

Journal Article
A1
open access

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial

Bob Lowenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, et al.

(2021) BLOOD ADVANCES. 5(4). p.1110-1121

Academic Bibliography

Tet2 is a tumor suppressor in the pre-leukemic phase of T-cell acute lymphoblastic leukemia

A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation

A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T : an EPICOVIDEHA survey

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL : the HOVON-100 trial

Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Myb drives B-cell neoplasms and myeloid malignancies in vivo

Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry : a multicentric study

G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML : the HOVON-SAKK-132 trial

Contents

Support

Contact